Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

ACC 2018, Day Three: Gout, Hypertension, and Diabetes Dominate Opening Late Breaker

News Conference News ACC 2018

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

Shelley Wood

March 12, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular News Stories for 2015

Shelley Wood

December 29, 2015

News Opinion Editor's Corner

Las 10 Noticias de TCTMD Más Leídas de 2015

Shelley Wood

December 29, 2015

News Conference News AHA 2015

Reversal Agents Safely Stop Effects of Novel Oral Anticoagulants

Yael L. Maxwell

November 10, 2015

News Daily News

RE-VERSE AD: Dabigatran Antidote Appears Safe, Effective in Interim Analysis

June 25, 2015

News Industry News

Portola Pharmaceuticals Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin C

June 25, 2015

News Daily News

Fallout from Bleeding Less Severe in Patients on Dabigatran Compared with Warfarin

Jason Kahn

October 04, 2013

News Daily News

Bivalirudin Bests Heparin for Lowering Bleeding Risk After CAS

L.A. McKeown

April 26, 2013

News Daily News

Meta-Analysis Shows Increased Risk of MI, ACS with Dabigatran

L.A. McKeown

January 09, 2012

News Daily News

Prothrombin Works as Antidote to Rivaroxaban, Not Dabigatran

L.A. McKeown

September 13, 2011

Advertisement

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

TCTMD’s Top 10 Most Popular News Stories for 2015

Las 10 Noticias de TCTMD Más Leídas de 2015

Reversal Agents Safely Stop Effects of Novel Oral Anticoagulants

RE-VERSE AD: Dabigatran Antidote Appears Safe, Effective in Interim Analysis

Portola Pharmaceuticals Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin C

Fallout from Bleeding Less Severe in Patients on Dabigatran Compared with Warfarin

Bivalirudin Bests Heparin for Lowering Bleeding Risk After CAS

Meta-Analysis Shows Increased Risk of MI, ACS with Dabigatran

Prothrombin Works as Antidote to Rivaroxaban, Not Dabigatran

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content